22 November 2022: Original Paper
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma
Gonzalo Sapisochin 1ADE** , Wei Chen Lee 2ABCDE , Dong Jin Joo 3ABD , Jae-Won Joh 4ABE , Koichiro Hata 56BCDE , Arvinder Singh Soin 7ACDE , Uday Kiran Veldandi 8ABCDEF , Shuhei Kaneko 9ACDE , Matthias Meier 10ACDEG , Denise Leclair 11DE , Gangadhar Sunkara 11CDEF , Long Bin Jeng 12AB**DOI: 10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
Table 5 Kaplan-Meier estimates of the proportion of subjects free from HCC recurrence or death (ITT).
| Time since LT | EVR+rTAC N=56 | sTAC N=61 | ||||
|---|---|---|---|---|---|---|
| Cumulative incidence rate | KM% estimation without event | Cumulative incidence rate | KM% estimation without event | |||
| n | KM% | (95% CI) | n | KM% | (95% CI) | |
| Week 4* | 0 | 100.0 | (100.0, 100.0) | 0 | 100.0 | (100.0, 100.0) |
| Month 12 | 2 | 96.3 | (91.3, 100.0) | 6 | 90.0 | (82.4, 97.6) |
| Month 24 | 6 | 88.4 | (79.7, 97.2) | 8 | 86.6 | (77.9, 95.2) |
| Month 36 | 6 | 88.4 | (79.7, 97.2) | 9 | 84.6 | (75.2, 93.9) |
| Month 48 | 7 | 86.2 | (76.7, 95.8) | 9 | 84.6 | (75.2, 93.9) |
| Month 60 | 7 | 86.2 | (76.7, 95.8) | 10 | 82.5 | (72.6, 92.4) |
| * Day of randomization i.e., start point. CI – confidence interval; EVR – everolimus; HCC – hepatic cell carcinoma; ITT – intent-to-treat; KM – Kaplan-Meier; LT – liver transplantation; n – number of patients with event; N – the total number of patients in the treatment group; rTAC – reduced dose tacrolimus; sTAC – standard dose tacrolimus. | ||||||